Increasing LV and AAV Titers to Meet Cell & Gene Therapy Needs

Increase LV and AAV Titers to Reduce Labor Costs and Meet Cell and Gene Therapy Demands
Gene therapies show great promise for treatment of disease, and transient transfection is a critical component for enabling the high titer and large-scale viral vector manufacturing processes that support these therapies.  We showcase a transfection solution and parameters intended to increae LV and AAV yields while decreasing costs through the use of less resources such as DNA and labor.

In this webinar, we outline the need for increasing manufacturing efficiency to generate sufficient doses for large patient populations and introduce the TransIT-VirusGEN^® Transfection Reagent and upcoming LV and AAV Enhancers along with critical parameters to meet this need in order to support cell and gene therapies.